BRIM Intermediate-Size Expanded Access
Brief description of study
This is an intermediate-size patient population expanded access application of 0.06% BRM421 Ophthalmic Solution for the treatment of Limbal Stem Cell Deficiency. no primary outcomes - intermediate-size patient population expanded access protocol no secondary outcomes - intermediate-size patient population expanded access protocol
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or